Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Lars Fruergaard Jørgensen says he is confident that Novo leads in terms of innovation in “each and every category” but comments: ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...

On a negative note, Novo Nordisk ousted CEO Lars Fruergaard Jorgensen in May amid increasing competition for the company's flagship anti-obesity drug. He'll remain in the role for the time being ...

Novo Nordisk (NVO) reached $69.82 at the closing of the latest trading day, reflecting a +1.16% change compared to its last close.

Lars Daniel, Director of Digital Forensics at Rimkus, is a recognized thought leader and digital forensics pioneer with more than 16 years of expertise transforming how the legal and insurance ...

SA Transcripts Fri, Nov. 05, 2021 Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2021 Results - Earnings Call Transcript SA Transcripts Wed, Nov. 03, 2021 ...